Peter Parker

Biography

 Peter is currently President, BioInnovation, LLC, a Cambridge, MA based provider of start-up capital and services to life sciences companies. For the past three decades, Peter has devoted his life to the amazing world of early stage company formation, funding and growth as an equity investor in over 30 companies. For the past 8 years, Peter has played a major role in the greater Boston/Cambridge healthcare start-up community. At MassChallenge, he has been the healthcare/life sciences ‘Champion’ from the outset, managing that vertical for the Boston accelerator. He is also one of three co-founders of LabCentral, Inc, a new not-for-profit for companies who need lab space in Kendall Sq. He is the founder of several start-ups, is a member of MassMedicalAngels, and is a reviewer for the Massachusetts Life Sciences Center Accelerator Loan program and for several other business plan competitions. Peter was a General Partner at Ampersand Ventures from 1988-2006 (now Sr. Advisor) and co-led the establishment of their life sciences franchise. The sectors where he has invested extensively include tools, devices, diagnostics, and therapeutics. At Ampersand, Peter provided the first institutional capital and was a Director in two dozen companies including; ACLARA Biosciences (IPO), Cyclis Pharmaceuticals (Chairman, sold to Arqule), Huntington Laboratories (Chairman, sold to EcoLab), NOVEX (Chairman, sold to Invitrogen), Panacos Pharmaceuticals (Chairman, public/reverse merger and PIPE with Vitex), Protein Ingredient Technologies (Chairman, sold to Associated British Foods). In 2006, Peter co-founded and was President and CEO of Cequent Pharmaceuticals, Inc (Cambridge, MA) which was sold to Marina Biotech (NSDQ: MRNA) in July, 2010. He has since invested in 12 local start-ups including Boston Heart Dx (Chairman) Klio Health, Veritas Genetics, 5G Bio, Deltix, Nova Molecular, Hope Dx, BioEssences, and AbVitro. Prior to Ampersand, Peter was head of worldwide R&D for AMAX Inc, a Fortune 50 industrial company. Peter holds a B.S. and an M.S. degree from Columbia University.

Research Interest

 Business